Pre-made Vobarilizumab benchmark antibody ( Bispecific Single Domains (VH-VH'), anti-IL6R;ALB therapeutic antibody, Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH’), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.
| Products Name (INN Index) | Pre-Made Vobarilizumab biosimilar, Bispecific Single Domains (VH-VH'), Anti-IL6R;ALB Antibody: Anti-CD126/HIES5/IL-1Ra/IL-6R/IL-6R-1/IL-6RA/IL6Q/IL6QTL/IL6RA/IL6RQ/gp80;FDAHT/HSA/PRO0883/PRO0903/PRO1 |
|---|---|
| INN Name | Vobarilizumab |
| Target | IL6R,ALB |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Ablynx |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Rheumatoid arthritis,Systemic lupus erythematosus |
| Development Tech | Nanobody Technology |
| Previous Name | NA |
| Gm Offical Target Name | IL6R,ALB |
| Package |
